Elevated soluble death receptor 5 can predict poor prognosis in patients with acute respiratory distress syndrome

作者：Jiangyue Qin, Hao Wang, Zhuoyao Lyu, Yue Liao, Ni Zeng, Ke Wang, Yongfang Zhou, Zijian Zeng, Zenglin Liao, Yu-Fang Cao, Junyun He, Tao Wang, Fuqiang Wen · 发表于：Expert Review of Respiratory Medicine · 年份：2022 · DOI：10.1080/17476348.2022.2100351 · 被引用次数：2 · 研究领域：Respiratory Support and Mechanisms、Cell death mechanisms and regulation、Phagocytosis and Immune Regulation

BACKGROUND: The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and its receptor, death receptor 5 (DR5), participate in pulmonary cell apoptosis. This study aimed to investigate the clinical value of soluble DR5 and TRAIL for prognosis assessment in acute respiratory distress syndrome (ARDS). RESEARCH DESIGN AND METHODS: Serum and bronchoalveolar lavage fluid (BALF) samples were collected from ARDS patients and controls. Patients were followed-up until death or discharge. Soluble DR5, TRAIL, TNF-α, soluble receptor for advanced glycation end-products (sRAGE), and albumin levels were measured using the Magnetic Luminex or enzyme-linked immunosorbent assays. Data were analyzed according to their distributions and statistical purposes. RESULTS: Serum and BALF DR5 levels were elevated in patients with ARDS; TRAIL elevation and reduction was observed in BALF and serum, respectively. Serum DR5 was higher in non-survivors compared to survivors. Serum DR5 was positively correlated with serum TNF-α and critical illness scores and negatively correlated with serum TRAIL. Serum DR5 exhibited potential for predicting mortality in patients with ARDS. CONCLUSIONS: Serum soluble DR5 elevation, a valuable prognosis predictor in ARDS, may be associated with alveolar epithelial cell apoptosis. TRIAL REGISTRATION: http://www.chictr.org.cn/index.aspx.Uniqueidentifier:ChiCTR-DDD-17013370.